Literature DB >> 19167182

A sensitive and rapid liquid chromatography-tandem mass spectrometry method for the quantification of the novel neurokinin-1 receptor antagonist aprepitant in rhesus macaque plasma, and cerebral spinal fluid, and human plasma with application in translational NeuroAIDs research.

Di Wu1, Dustin J Paul, Xianguo Zhao, Steven D Douglas, Jeffrey S Barrett.   

Abstract

A sensitive and rapid liquid chromatography-tandem mass spectrometry method has been developed for to assess therapeutic exposures of aprepitant in HIV-infected patients and rhesus macaques. The method utilized a simple sample-preparation procedure of protein precipitation with methanol. Chromatographic separation was performed on a reversed phase C(8) column (Hypersil Gold, 50 mm x 2.1 mm, 3 microm) using a mobile phase composed of acetonitrile and water in 0.5% formic acid through gradient elution. Electro-spray ionization in positive mode was incorporated in the tandem mass spectrometric detection. The lower limit of quantitation of aprepitant in plasma of rhesus macaques and human and cerebral spinal fluid of rhesus macaques were 1, 1, and 0.1 ng/mL, respectively. The method has been successfully employed to measure aprepitant in preclinical and clinical samples collected from three SIV-infected rhesus macaques and ten patients with HIV infection. In conclusion, this liquid chromatography-tandem mass spectrometry method is suitable for preclinical-clinical translational research exploring exposure-response relationships with aprepitant as well as therapeutic drug monitoring of aprepitant.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19167182      PMCID: PMC2883891          DOI: 10.1016/j.jpba.2008.12.005

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  5 in total

1.  Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes.

Authors:  J P Lai; W Z Ho; G X Zhan; Y Yi; R G Collman; S D Douglas
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Determination of a novel substance P inhibitor in human plasma by high-performance liquid chromatography with atmospheric pressure chemical ionization mass spectrometric detection using single and triple quadrupole detectors.

Authors:  M L Constanzer; C M Chavez-Eng; J Dru; W F Kline; B K Matuszewski
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-08-05       Impact factor: 3.205

Review 3.  Substance P and neurokinin-1 receptor modulation of HIV.

Authors:  Wen-Zhe Ho; Steven D Douglas
Journal:  J Neuroimmunol       Date:  2004-12       Impact factor: 3.478

4.  Simultaneous determination of Aprepitant and two metabolites in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection.

Authors:  C M Chavez-Eng; M L Constanzer; B K Matuszewski
Journal:  J Pharm Biomed Anal       Date:  2004-09-03       Impact factor: 3.935

Review 5.  Facilitating compound progression of antiretroviral agents via modeling and simulation.

Authors:  Jeffrey S Barrett
Journal:  J Neuroimmune Pharmacol       Date:  2007-01-17       Impact factor: 4.147

  5 in total
  6 in total

1.  In vitro glucuronidation of aprepitant: a moderate inhibitor of UGT2B7.

Authors:  Larry House; Jacqueline Ramirez; Michael Seminerio; Snezana Mirkov; Mark J Ratain
Journal:  Xenobiotica       Date:  2015-06-08       Impact factor: 1.908

2.  Antiinflammatory effects of aprepitant coadministration with cART regimen containing ritonavir in HIV-infected adults.

Authors:  Sergei Spitsin; Pablo Tebas; Jeffrey S Barrett; Vasiliki Pappa; Deborah Kim; Deanne Taylor; Dwight L Evans; Steven D Douglas
Journal:  JCI Insight       Date:  2017-10-05

3.  A randomized, placebo controlled, double masked phase IB study evaluating the safety and antiviral activity of aprepitant, a neurokinin-1 receptor antagonist in HIV-1 infected adults.

Authors:  Pablo Tebas; Florin Tuluc; Jeffrey S Barrett; Wayne Wagner; Deborah Kim; Huaquing Zhao; René Gonin; James Korelitz; Steven D Douglas
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

4.  Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV.

Authors:  Jeffrey S Barrett; Sergei Spitsin; Ganesh Moorthy; Kyle Barrett; Kate Baker; Andrew Lackner; Florin Tulic; Angela Winters; Dwight L Evans; Steven D Douglas
Journal:  J Transl Med       Date:  2016-05-26       Impact factor: 5.531

5.  Pharmacological modulation of brain activation to non-noxious stimulation in a cynomolgus macaque model of peripheral nerve injury.

Authors:  Aldric Hama; Mizuho Yano; Wakana Sotogawa; Rintaro Fujii; Yuji Awaga; Takahiro Natsume; Ikuo Hayashi; Hiroyuki Takamatsu
Journal:  Mol Pain       Date:  2021 Jan-Dec       Impact factor: 3.395

6.  Reduction of soluble CD163, substance P, programmed death 1 and inflammatory markers: phase 1B trial of aprepitant in HIV-1-infected adults.

Authors:  Pablo Tebas; Sergei Spitsin; Jeffrey S Barrett; Florin Tuluc; Okan Elci; James J Korelitz; Wayne Wagner; Angela Winters; Deborah Kim; Renae Catalano; Dwight L Evans; Steven D Douglas
Journal:  AIDS       Date:  2015-05-15       Impact factor: 4.177

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.